191 related articles for article (PubMed ID: 10920970)
21. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer.
Kim R; Osaki A; Toge T
Oncol Rep; 2003; 10(1):145-50. PubMed ID: 12469161
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
[TBL] [Abstract][Full Text] [Related]
23. Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel.
Juan O; Albert A; Campos JM; Caranyana V; Muñoz J; Alberola V
Acta Oncol; 2007; 46(3):367-73. PubMed ID: 17450473
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.
Yamamoto N; Tsurutani J; Yoshimura N; Asai G; Moriyama A; Nakagawa K; Kudoh S; Takada M; Minato Y; Fukuoka M
Anticancer Res; 2006; 26(1B):777-81. PubMed ID: 16739353
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
Hájek R; Vorlicek J; Slavik M
Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
[TBL] [Abstract][Full Text] [Related]
28. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
[TBL] [Abstract][Full Text] [Related]
29. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
Noda K; Ikeda M; Kudo R; Nishiya I; Yajima A; Tanaka K; Kodama S; Takahashi T; Tokunaga A; Satoh I; Nozawa S; Taketani Y; Terashima Y; Isonishi S; Takeda Y; Nishijima M; Kuroshima Y; Fujii S; Izumi R; Tamaya T; Mori T; Okada H; Ogita S; Ozaki M; Hatae M
Gan To Kagaku Ryoho; 1996 Feb; 23(3):317-25. PubMed ID: 8712825
[TBL] [Abstract][Full Text] [Related]
30. The pharmacoeconomics of cancer therapies.
Bishop JF; Macarounas-Kirchman K
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
[TBL] [Abstract][Full Text] [Related]
31. A feasibility study of 1-h paclitaxel infusion in patients with solid tumors.
Tsavaris N; Polyzos A; Kosmas C; Giannikos L; Gogas J
Cancer Chemother Pharmacol; 1997; 40(4):353-7. PubMed ID: 9225955
[TBL] [Abstract][Full Text] [Related]
32. [China-made paclitaxel in the treatment of advanced ovarian cancer: a clinical analysis of 32 cases].
Liu L; Hong W; Zhang R
Zhonghua Fu Chan Ke Za Zhi; 1997 Apr; 32(4):222-5. PubMed ID: 9596903
[TBL] [Abstract][Full Text] [Related]
33. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
34. [Paclitaxel (Tesu) as a single agent in the treatment of breast cancer].
Jiang Z; Song S; Liu X
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):445-7. PubMed ID: 10920879
[TBL] [Abstract][Full Text] [Related]
35. One-hour paclitaxel infusions: review of safety and efficacy.
Greco FA; Thomas M; Hainsworth JD
Cancer J Sci Am; 1999; 5(3):179-91. PubMed ID: 10367176
[TBL] [Abstract][Full Text] [Related]
36. Overview of paclitaxel (Taxol) in advanced lung cancer.
Ettinger DS
Semin Oncol; 1993 Aug; 20(4 Suppl 3):46-9. PubMed ID: 8102017
[TBL] [Abstract][Full Text] [Related]
37. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
38. [Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non-small-cell lung cancer].
Chen Q; Zhang QZ; Liu J; Li LQ; Zhao WH; Wang YJ; Zhou QH; Li L
Zhonghua Zhong Liu Za Zhi; 2003 Mar; 25(2):190-2. PubMed ID: 12795852
[TBL] [Abstract][Full Text] [Related]
39. Taxol improves outlook for lung, breast, and ovarian cancer.
Oncology (Williston Park); 1992 Aug; 6(8):16. PubMed ID: 1354469
[No Abstract] [Full Text] [Related]
40. [Paclitaxel].
Díaz M; Campanero MA
Rev Med Univ Navarra; 1996; 40(3):43-51. PubMed ID: 9499826
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
